Therefore, we successfully demonstrated that a combination treatment approach involving the use of Srx–Prx redox system-targeting compounds, such as frugoside, and anticancer drugs, is a promising and novel therapeutic strategy for colon cancer treatment. Here, SRXN1 is linked to malignant colon neoplasm.